MarketPeel
Insider Trading Intelligence
Pricing
…
CC

Craig A. Collard

HRTX
CHIEF EXECUTIVE OFFICER · HERON THERAPEUTICS, INC. /DE/ · CIK 0001363558
FILING MIX · LIFETIME58%/42%
BUYS
28
SELLS
20
TOTAL VALUE
$140.1K
COMPANIES
1
ACTIVE SINCE
Apr 2023
HOLDINGS NOW
382,675
AVG SELL PX
$1.55
TRADE KIND
SHOWING 48 / 48
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons
Forward-return performance of every backtestable P/S trade by Craig A. Collard, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%+49.43%+1.06%+48.37%+48.37%—
14d1+100.00%+34.16%+1.37%+32.79%+32.79%—
30d1+100.00%+97.43%+4.67%+92.76%+92.76%—
60d1+100.00%+139.97%+5.91%+134.05%+134.05%—
90d1+100.00%+196.68%+11.19%+185.50%+185.50%—
180d1+100.00%+206.50%+17.06%+189.44%+189.44%—
1y1+100.00%+29.80%+31.86%-2.06%-2.06%—
2y1+100.00%+19.98%+52.23%-32.24%-32.24%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
HRTX · 382,675 shares · as of Apr 30, 2026
01,062,5002,125,0003,187,5004,250,000202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 28 buys / 20 sellsCOVERAGE · 13 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Chief Executive Officer
34,789——696,841Apr 30, 2026May 4, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
50,021——750,316Apr 30, 2026May 4, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Chief Executive Officer
50,021——757,885Apr 30, 2026May 4, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
34,789——382,675Apr 30, 2026May 4, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
13,797——96,758Apr 19, 2026Apr 21, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Chief Executive Officer
13,797——662,052Apr 19, 2026Apr 21, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Chief Executive Officer
62,500——648,255Apr 3, 2026Apr 6, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
62,500——62,500Apr 3, 2026Apr 6, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Chief Executive Officer
34,789——571,710Jan 31, 2026Feb 3, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
34,789——417,464Jan 31, 2026Feb 3, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
800,336——800,336Jan 30, 2026Feb 3, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
800,337——800,337Jan 30, 2026Feb 3, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
13,797——110,375Jan 19, 2026Jan 20, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Chief Executive Officer
13,797——536,921Jan 19, 2026Jan 20, 2026 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Chief Executive Officer
34,789——523,124Oct 31, 2025Nov 4, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
34,789——452,253Oct 31, 2025Nov 4, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Chief Executive Officer
13,797——488,335Oct 19, 2025Oct 21, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
13,797——124,172Oct 19, 2025Oct 21, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Chief Executive Officer
34,789——474,538Jul 31, 2025Aug 4, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
34,789——487,042Jul 31, 2025Aug 4, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Chief Executive Officer
13,797——439,749Jul 19, 2025Jul 22, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
13,797——137,969Jul 19, 2025Jul 22, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Chief Executive Officer
34,789——425,952Apr 30, 2025May 2, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
34,789——521,831Apr 30, 2025May 2, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Chief Executive Officer
13,796——391,163Apr 19, 2025Apr 22, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
13,796——151,766Apr 19, 2025Apr 22, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
62,500——125,000Apr 3, 2025Apr 3, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Chief Executive Officer
62,500——377,367Apr 3, 2025Apr 3, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
556,620——556,620Jan 31, 2025Feb 4, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
1,113,240——1,113,240Jan 31, 2025Feb 4, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
13,797——165,562Jan 19, 2025Jan 22, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Chief Executive Officer
13,797——314,867Jan 19, 2025Jan 22, 2025 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Chief Executive Officer
13,797——290,387Oct 19, 2024Oct 21, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
13,797——179,359Oct 19, 2024Oct 21, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Chief Executive Officer
13,797——276,590Jul 19, 2024Jul 22, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
13,797——193,156Jul 19, 2024Jul 22, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Chief Executive Officer
13,797——262,793Apr 19, 2024Apr 19, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Chief Executive Officer
62,500——248,996Apr 3, 2024Apr 5, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
62,500——187,500Apr 3, 2024Apr 5, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
220,750——220,750Jan 19, 2024Jan 19, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
1,324,502——1,324,502Jan 19, 2024Jan 19, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
13,797——206,953Jan 19, 2024Apr 19, 2024 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASE
Chief Executive Officer
150,000$0.92$138.0K186,496Nov 16, 2023Nov 17, 2023 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
692$1.65$1.1K36,496Aug 22, 2023Aug 24, 2023 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
SALE
Chief Executive Officer
691$1.45$1.0K37,188May 22, 2023May 24, 2023 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
4,250,000——4,250,000Apr 3, 2023Apr 5, 2023 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
3,000,000——3,000,000Apr 3, 2023Apr 5, 2023 ↗View →
HRTX
HERON THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
250,000——250,000Apr 3, 2023Apr 5, 2023 ↗View →
Other insiders · HRTX
Loading peer insiders…
About this filer
CIK 0001363558
ROLE
Chief Executive Officer
PRIMARY
HRTX
COMPANIES
1
ACTIVE SINCE
Apr 2023
MARKETPEEL · /INSIDER/0001363558DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback